Calcifediol Receptor Binding for ARDS Mortality Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for acute respiratory distress syndrome (ARDS) associated with SARS-CoV-2 infection are ineffective in reducing mortality and improving patient outcomes, with existing treatments like inhaled nitric oxide, prostacyclins, and corticosteroids showing limited benefits or adverse effects.
Innovation Solution
The use of calcifediol, a vitamin D receptor agonist, which acts as a substrate for the synthesis of calcitriol, binding with high affinity to the vitamin D receptor to regulate gene transcription and exert broad biological actions, offering a superior therapeutic approach by mitigating inflammatory processes and improving immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Temperature
If inhaled nitric oxide is used to improve oxygenation in ARDS patients, then oxygenation may be temporarily improved, but adverse effects such as methemoglobinemia, cytotoxic nitrogen products, and kidney failure occur
Solution Approach 1:
The patent employs inhaled nitric oxide as a temporary, short-acting therapeutic agent that provides acute oxygenation improvement but is intentionally limited in duration and dosage to minimize cumulative toxicity. The drug is administered only when needed and discontinued once therapeutic effect is achieved, accepting the trade-off of temporary adverse effects for life-saving oxygenation support.
Solution Approach 2:
The patent carefully controls the concentration and dosage parameters of inhaled nitric oxide to achieve therapeutic oxygenation while staying below thresholds that cause severe adverse effects. By adjusting the partial pressure and inhalation duration, the treatment optimizes the benefit-risk ratio for each patient condition.
2Object-generated harmful factors
If corticosteroids are administered to reduce inflammation in ARDS, then inflammatory response may be suppressed, but treatment effectiveness is limited and potential adverse effects occur
Solution Approach 1:
The patent uses corticosteroids as an intermediary anti-inflammatory agent that modulates the immune response without completely suppressing it. The steroid molecules act as mediators between the overactive immune system and the damaged lung tissue, reducing inflammation while preserving some immune function to prevent secondary infections.
Solution Approach 2:
The patent employs corticosteroids at doses and durations calibrated to provide partial anti-inflammatory action rather than complete suppression. This partial action is sufficient to reduce the harmful cytokine storm while minimizing the risk of severe adverse effects and maintaining some protective immune responses.
3Ease of operation
If existing therapeutic options are used for ARDS, then some symptomatic relief may be achieved, but mortality reduction and significant outcome improvement are not accomplished
Solution Approach 1:
The patent segments the ARDS treatment approach into multiple targeted components: antiviral therapy to address the underlying infection, anti-inflammatory agents to control the cytokine storm, respiratory support to maintain oxygenation, and complication prevention. This segmented multi-modal approach addresses both symptomatic relief and mortality reduction by treating different pathophysiological aspects simultaneously.
Solution Approach 2:
The patent employs a composite therapeutic regimen combining multiple drug classes and treatment modalities rather than relying on a single intervention. The combination of antivirals, corticosteroids, respiratory support, and supportive care creates a synergistic effect that achieves both symptomatic improvement and mortality reduction beyond what any single treatment could accomplish alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Calcifediol demonstrates clinically and statistically significant improvements in patient outcomes, reducing the need for ICU admission, mortality, and hospital stay duration, with a safer and more effective profile compared to other vitamin D forms and existing treatments for ARDS.
Implementation Method 1
binding with high affinity to the vitamin D receptor to regulate gene transcription
Data Source
AI summary
The invention relates to calcifediol for the prophylaxis and/or treatment of acute respiratory distress syndrome.